Oncology Today with Dr Neil Love cover image

Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Ovarian Cancer Issue

Oncology Today with Dr Neil Love

00:00

The Tolerance of UPRI in Patients With Platinum Resistance

The original dosing was at 42 and what we decided on from a safety standpoint and further development is at 36 for the platinum resistant patients. Now interestingly because of the maintenance setting in up next in their platinum sensitive that they utilize 30 milligrams per meter squared to treat them. You've used UPRI in clinical trials? Yeah use it quite a bit we're one of the highest in rollers in the previous trial.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app